PROSCA & BLADDR 2022

 

PROSCA & BLADDR 2022
T

Urinary Biomarkers in Bladder Cancer Surveillance: Where Do We Stand?

By PROSCA & BLADDR 2022 FEATURING Tobias Klatte
By PROSCA & BLADDR 2022 FEATURING Tobias Klatte
0 views
December 28, 2022
Comments 0
Login to view comments. Click here to Login
BLADDR
23:04
PROSCA & BLADDR 2022

Neoadjuvant Systemic Therapy for MIBC

Feat. T. Powles
14:45
PROSCA & BLADDR 2022

Update on Perioperative Systemic Therapies for UTUC

Feat. K. Gust
15:26
PROSCA & BLADDR 2022

New Roadmaps for Bladder Preservation in High-Risk NMIBC in 2022

Feat. J. Irani
13:03
PROSCA & BLADDR 2022

The Role of Systemic Therapy for Bladder Preservation Strategies in …

Feat. A. Bamias
06:54
PROSCA & BLADDR 2022

Intravesical IO in High Risk NMIBC: A HGUCG Study

Feat. C. Fragkoulis
28:06
PROSCA & BLADDR 2022

Multidisciplinary Management of Pts With MIBC: Real World Patient Ca…

Feat. M. De Santis, A. Choudhury, A. Drakaki, T. Klatte
10:09
PROSCA & BLADDR 2022

Transurethral Resection of Bladder Tumor

Feat. M. Moschini
13:52
PROSCA & BLADDR 2022

Genomic and Tumor Characterisation of UTUC

Feat. E. Comperat
11:57
PROSCA & BLADDR 2022

Clinical Utility of ctDNA Analysis in Bladder Cancer

Feat. B. Szabados
12:57
PROSCA & BLADDR 2022

The Role of Palliative and Best Supportive Care in Bladder Cancer

Feat. D. De Maeseneer
16:45
PROSCA & BLADDR 2022

Lessons From Failed Clinical Trials for Bladder Cancer

Feat. R. Jones
38:03
PROSCA & BLADDR 2022

Multiple Cases Discussion: Oligometastatic Bladder Cancer

Feat. V. Fonteyne, K. Gust, U. Vogl, P. Grivas
15:42
PROSCA & BLADDR 2022

Transurethral Resection of Bladder Tumor: Challenges and Opportuniti…

Feat. M. Moschini
14:03
PROSCA & BLADDR 2022

Considerations for Radical Cystectomy

Feat. B. Konety
17:44
PROSCA & BLADDR 2022

RT of the Bladder: Clinical Practice and Recent Advancements

Feat. A. Choudhury
12:39
PROSCA & BLADDR 2022

The Emerging Role of Maintenance Therapy in Bladder Cancer

Feat. R. Jones
16:02
PROSCA & BLADDR 2022

The Growing Landscape of Antibody-Drug Conjugates in Advanced UC

Feat. P. Grivas
13:35
PROSCA & BLADDR 2022

Clarifying the Position of Immunotherapies for mUC

Feat. B. Szabados
06:37
PROSCA & BLADDR 2022

DEBATE: Are We Evolving Towards a Platinum-Free Future in Bladder Ca…

Feat. M. De Santis
07:13
PROSCA & BLADDR 2022

DEBATE: Are We Evolving Towards a Platinum-Free Future in Bladder Ca…

Feat. A. Bamias
07:19
PROSCA & BLADDR 2022

Final Results of the HIVEC-HR Randomised Trial Comparing Hyperthermi…

Feat. F. Guerrero-Ramos
05:26
PROSCA & BLADDR 2022

Concurrent CRT for MIBC Using 5-Fluorouracil vs. Capecitabine: A Nat…

Feat. L. van Hoogstraten
10:43
PROSCA & BLADDR 2022

Assessment of Molecular Biomarkers for Bladder Cancer Diagnosis, Pro…

Feat. H. El Ahanidi
23:34
PROSCA & BLADDR 2022

Bladder Cancer Case Discussion: Staging and Follow-Up of Pts With No…

Feat. T. Klatte, D. Mitropoulos, J. Irani, R. Meijer, M. Moschini, N. James
08:46
PROSCA & BLADDR 2022

Bladder Cancer: Is It Time to Revise the Pathway?

Feat. N. James
09:34
PROSCA & BLADDR 2022

Radical Cystectomy With Ileal Conduit: Lessons to Be Learned

Feat. R. Meijer
10:19
PROSCA & BLADDR 2022

Uro-Stoma Care: Where Are We Now

Feat. B. Thoft Jensen
15:01
PROSCA & BLADDR 2022

Urinary Biomarkers in Bladder Cancer Surveillance: Where Do We Stand?

Feat. T. Klatte